Shanghai Ark Biopharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-04-29
- Employees
- 51
- Market Cap
- -
A Study of AK0529 in Adults Patients Hospitalized With RSV Infection
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT06942299
- Locations
- 🇨🇳
Guizhou People's Hospital, Guiyang, Guizhou, China
🇨🇳The Second Perople's Hospital of Hefei, Hefei, Anhui, China
🇨🇳Huangshan City People's Hospital, Huangshan, Anhui, China
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
- Conditions
- Respiratory Synctial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06775405
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, China
🇨🇳First Hospital of Jilin University, Changchun, China
🇨🇳Hunan Provincial People's Hospital, Changsha, China
Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06591845
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06359899
- Locations
- 🇨🇳
Beijing anding hospital capital medical university, Beijing, Beijing, China
🇨🇳Peking university sixth hospital, Beijing, Beijing, China
A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05434897
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital,Shanghal JiaoTong University School of Medicine, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT05424887
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
A Study of AK3280 in Chinese Healthy Volunteers
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04926116
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04788017
- Locations
- 🇺🇸
Frontage, Secaucus, New Jersey, United States
A Study of AK0529 in Chinese Infants Hospitalized With RSV
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Matching placebo of AK0529
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 311
- Registration Number
- NCT04231968
- Locations
- 🇨🇳
The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China
🇨🇳Hunan Provincial People's Hospital, Changsha, China
🇨🇳Henan Children's Hospital, Zhengzhou, China
A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03990688
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden